Placeholder Banner

2016 BIO World Congress on Industrial Biotechnology Exhibition Hall to Feature NSF Small Business Innovation Research Companies

March 28, 2016

Washington, D.C. (March 28, 2016) The Biotechnology Innovation Organization (BIO) in partnership with the National Science Foundation (NSF) will feature Small Business Innovation Research (SBIR) funded early-stage industrial biotech companies at BIO’s 13thAnnual World Congress on Industrial Biotechnology.  The world’s largest industrial biotechnology event will be held April 17-20, 2016 at the San Diego Convention Center in San Diego, CA.

“BIO and NSF have established a great public/private partnership, which first debuted at the 2013 BIO Investor Forum and will now be showcased at the 2016 BIO World Congress on Industrial Biotechnology,” said Brent Erickson, executive vice president for BIO’s Industrial & Environmental Section. “Through the SBIR grant program, qualified companies can move forward and bring innovative technologies to market. I hope everyone at the World Congress will take the time to stop by and learn about these exciting companies. ”

“The BIO World Congress on Industrial Biotechnology is an excellent opportunity for these companies to showcase their cutting-edge technologies, form long-term partnerships and begin to raise funds in the private sector,” said Jesus Soriano, MD, PhD, MBA, a program director for NSF's SBIR/STTR program. “NSF’s SBIR/STTR Program shows the government and private sectors working together toward the common goals of spurring job growth, building a bioeconomy, and reducing the costs and environmental footprint of manufacturing.” 

Each of the companies has been rigorously vetted through the SBIR NSF merit review process prior to receiving the funding. The NSF-SBIR Table Top and Poster Presentation Area located within the Exhibition will feature participating companies who have received SBIR Phase II grants. Phase II funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the project proposed in Phase II. Companies can qualify for up to $1 million dollars in funding to engage in R&D that has the potential for commercialization.

All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

For more information on the conference, please visit http://go.bio.org/WorldCongress2016.html. For assistance, please contact worldcongress@bio.org.

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

    Discover More
    BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
    “The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
    BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…